Stock itci.

Intra-Cellular Therapeutics ITCI is a biopharma company focused on discovering, ... and minimal competition in its target market is likely to keep the stock afloat in the long term.On January 10, 2020, the Company completed a public offering of common stock in which the Company sold 10,000,000 shares of common stock at an offering price of $ 29.50 per share for aggregate gross proceeds of $ 295.0 million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were …The stock of Intra-Cellular Therapies Inc (ITCI) has gone up by 5.10% for the week, with a -1.20% drop in the past month and a -13.62% drop in the past quarter. The volatility ratio for the week is 5.20%, and the volatility levels for the past 30 days are 3.88% for ITCI. The simple moving average foAs of Jun 30, 2023, ITCI had cash, cash equivalents, restricted cash and investment securities of $514.6 million compared with $540.5 million as of Mar 31, 2023. 2023 Guidance UpdatedIntra-Cellular Therapies, Inc. (ITCI) Stock Price, Quote & News - Stock Analysis NASDAQ: ITCI · IEX Real-Time Price · USD -0.01 (-0.02%) Nov 15, 2023, 4:00 …

A. The latest price target for Intra-Cellular Therapies ( NASDAQ: ITCI) was reported by RBC Capital on Friday, November 3, 2023. The analyst firm set a price target for 76.00 expecting ITCI to ...ITCI is a biopharmaceutical company that develops novel drugs for treating neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system. On August 22, 2022, The Goldman Sachs Group Inc. ( GS ) downgraded ITCI from a “buy” rating to a “neutral” rating.

Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Insider Sell: Sharon Mates Sells 100,000 Shares of Intra-Cellular Therapies Inc. On September 19, 2023, Sharon Mates, Chairman, President & CEO of Intra-Cellular Therapies Inc (NASDAQ:ITCI), sold ...

According to . 5 Wall Street analysts that have issued a 1 year ITCI price target, the average ITCI price target is $78.20, with the highest ITCI stock price forecast at $101.00 and the lowest ITCI stock price forecast at $62.00.Stock control is important because it prevents retailers from running out of products, according to the Houston Chronicle. Stock control also helps retailers keep track of goods that may have been lost or stolen.Intra-Cellular Therapies Market Cap: 5.69B, Enterprise value: 5.39B, P/E: -21.66, PEG ratio: -0.97, EPS: -1.54, Revenue: 418.10M, EBITDA: -172.56M, ...Oct 9, 2023 · Intra-Cellular Therapies (ITCI) Jefferies analyst Andrew Tsai maintained a Buy rating on Intra-Cellular Therapies on October 6 and set a price target of $95.00 . The company’s shares closed last ...

ITCI has received 7 recent reviews, and they all concur – this is a stock to buy, making the Strong Buy consensus view unanimous. The shares are priced at $50.8 and the $62.71 average price ...

ITCI - Free Report) shares were up 2% on May 5, after the company reported better-than-expected first-quarter 2023 results on May 4. ITCI incurred a loss of 46 cents per share in the reported ...

Based on analysts offering 12 month price targets for ITCI in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .Headquartered in Chelmsford, Massachusetts, Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) is a sample exploration and management solutions provider for the life science market. On November 23, 2022 ...ITCI has received 7 recent reviews, and they all concur – this is a stock to buy, making the Strong Buy consensus view unanimous. The shares are priced at $50.8 and the $62.71 average price ...Mar 28, 2023 · 04:20 PM ET 03/28/2023. Intra-Cellular Therapies ( ITCI) said Tuesday that its depression treatment succeeded in a key study, and ITCI stock broke definitively above its 200-day line for the first ... Intra-Cellular Therapies Inc. 430 East 29th Street. Suite 900. New York, New York 10016. Phone 1 464 440-9333. Industry Pharmaceuticals. Sector Health Care/Life Sciences. Fiscal Year-end 12/2023 ...

With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.Nov 2, 2023 · ITCI reported total revenues of $126.2 million for Q3 2023, compared to $71.9 million for the same period in 2022. ... is selling $2 billion of stock in Las Vegas Sands Corp. so the family can ... Nov 3, 2022 · Intra-Cellular (ITCI) delivered earnings and revenue surprises of 33.72% and 10.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? Find the latest Intra-Cellular Therapies, Inc. (ITCI) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Get up to 10 years of daily historical stock prices & volumes. The "Close/Last" is the “adjust consolidated close price”. Data provided by Edgar Online. The net and percent change in the quote ...Nov 7, 2023 · by Zacks Equity Research Published on November 07,2023. The mean of analysts' price targets for Intra-Cellular (ITCI) points to a 41.2% upside in the stock. While this highly sought-after metric ... NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will hold its 2020 Annual Meeting of Stockholders (the “Annual …

Intra-Cellular Therapies (ITCI) Stock Forecast, Price Targets ... Intra-Cellular Therapies Market Cap: 5.69B, Enterprise value: 5.39B, P/E: -21.66, PEG ratio: -0.97, EPS: -1.54, Revenue: 418.10M, EBITDA: -172.56M, ...

Intra-Cellular Therapies ( NASDAQ: ITCI) stock traded much higher recently after it had obtained FDA approval for its drug CAPLYTA (lumateperone) for the treatment of adults with bipolar ...Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting ...ITCI, -14836.0 shares, $-823694.72, 2023-08-31, N-PORT. No recent transactions ... Stock Lookup. Enter stock name: use * for wildcard.In the past 90 days, the Zacks Consensus Estimate for Aptinyx’s 2023 loss per share has narrowed from 77 cents to 47 cents. In the past year, shares of Aptinyx have fallen by 86.8%. APTX beat ...Nov 17, 2023 · Stock Ideas and Recommendations. Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools IntraCellular Therapies (ITCI) Quote Overview » More Research » IntraCellular Therapies (ITCI) Full Company Report Better trading starts here. Company SummaryDespite the negative momentum in the past three months at -12.40%, the 6 and 9-month momentum are positive at +19.58% and +14.86% respectively, contrasting slightly with the stock's minor decline ...Shares of Intra-Cellular Therapies (ITCI) have gained 7.7% over the past four weeks to close the last trading session at $56.01, but there could still be a solid upside left in the stock if short ...ITCI The Nasdaq Global Select Market ... Common stock, $ 0.0001 par value: 175,000,000 and 100,000,000 shares authorized at September 30, 2021 and December 31, 2020, ...

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.

Christopher Alafi ITCI stock SEC Form 4 insiders trading. Christopher has made over 21 trades of the Intra-Cellular Therapies Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 47,325 units of ITCI stock worth $1,897,733 on 27 May 2021.. The largest trade he's ever made was buying 625,000 units …

NEW YORK, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, …The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in New York, NY. ITCI - Intra-Cellular Therapies Inc - Stock screener for investors and traders, financial visualizations.The Zacks Consensus Estimate for ITCI's full-year earnings has moved 14% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.Intra-Cellular Therapies Inc. Common Stock (ITCI) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) reported Q3 2023 total revenues of $126.2 million, a 75% increase compared to the same period in 2022. CAPLYTA Q3 2023 net product sales were $125.8 million, representing a 75% increase. CAPLYTA total prescriptions increased 71% in Q3 2023.TimesSquare Capital highlighted stocks like Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) in its Q3 2022 investor letter. Headquartered in New York, New York, Intra-Cellular Therapies, Inc ...Nov 24, 2023 · The Intra-Cellular Therapies Inc. stock price gained 0.270% on the last trading day (Friday, 24th Nov 2023), rising from $59.26 to $59.42. During the last trading day the stock fluctuated 2.29% from a day low at $58.96 to a day high of $60.31. The price has risen in 6 of the last 10 days and is up by 11.02% over the past 2 weeks. Dec 1, 2023 · Earnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($1.68) to ($0.80) per share. Intra-Cellular Therapies has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 6th, 2024 based off prior year's report dates. Read More. Find the latest Financials data for Intra-Cellular Therapies Inc. Common Stock (ITCI) at Nasdaq.com. Intra-Cellular Therapies Inc. Common Stock (ITCI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. ITCI has a Quality Grade of D, ranking ahead of 18.25% of graded US stocks. ITCI's asset turnover comes in at 0.08 -- ranking 278th of 682 Pharmaceutical Products stocks. …sdominick. Introduction. Intra-Cellular Therapies (NASDAQ:ITCI), a pioneering biotech firm, is dedicated to the creation and market introduction of novel small molecule therapies, which are ...

Oct 26, 2023 · Intra-Cellular Therapies Inc’s trailing 12-month revenue is $365.8 million with a -50.4% profit margin. Year-over-year quarterly sales growth most recently was 99.3%. Analysts expect adjusted earnings to reach $-2.089 per share for the current fiscal year. Intra-Cellular Therapies Inc does not currently pay a dividend. SVB Securities analyst Marc Goodman reiterated a Buy rating on Intra-Cellular Therapies (ITCI – Research Report) yesterday and set a price target of $70.00.The company’s shares opened today at ...Nov 7, 2023 · Shares of Intra-Cellular Therapies (ITCI) have gained 7.7% over the past four weeks to close the last trading session at $56.01, but there could still be a solid upside left in the stock if short ... ITCI, -14836.0 shares, $-823694.72, 2023-08-31, N-PORT. No recent transactions ... Stock Lookup. Enter stock name: use * for wildcard.Instagram:https://instagram. how to invest in mls socceris amazon stock going to go uppractice investingimax price Aug 4, 2023 · As of Jun 30, 2023, ITCI had cash, cash equivalents, restricted cash and investment securities of $514.6 million compared with $540.5 million as of Mar 31, 2023. 2023 Guidance Updated transcendentelectrahomesamerican tower reit by Zacks Equity Research Published on November 07,2023. The mean of analysts' price targets for Intra-Cellular (ITCI) points to a 41.2% upside in the stock. While this highly sought-after metric ... automated stock trading app Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up Zacks - Wed Mar 29, 11:27AM CDT . Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.Nov 22, 2023 · The latest Intra-Cellular Therapies stock prices, stock quotes, news, and ITCI history to help you invest and trade smarter. The firm decreased its portfolio allocation in ITCI by 99.89% over the last quarter. ITOT - iShares Core S&P Total U.S. Stock Market ETF holds 89K shares representing 0.09% ownership of the company.